Cardio-Facio-Cutaneous Syndrome: Evaluation and Management
Patients with suspected cardio-facio-cutaneous syndrome require immediate genetics consultation with multigene Ras/MAPK pathway panel testing (BRAF, MEK1, MEK2, KRAS), alongside urgent cardiology evaluation with echocardiogram and electrocardiogram, followed by coordinated multidisciplinary subspecialty care targeting the syndrome's life-threatening cardiac, neurologic, and growth complications. 1
Initial Diagnostic Evaluation
Genetic Testing Algorithm
When CFC is suspected based on clinical presentation, proceed systematically:
- First-line: Multigene Ras/MAPK pathway panel testing (approximately 80% mutation detection rate) 1
- If panel unavailable: Sequential testing: (1) BRAF, (2) MEK1 and MEK2, (3) KRAS 1
- If negative: High-resolution chromosome microarray 1
- If still negative: Consider whole exome sequencing 1
- If variant of uncertain significance detected: Parental testing required 1
The genetic heterogeneity demands this stepwise approach, as BRAF mutations are most common (62%), followed by MAP2K1 (28%) and MAP2K2 (10%) 2.
Clinical Recognition Features
Look specifically for this constellation that distinguishes CFC from other RASopathies:
Craniofacial: Macrocephaly/relative macrocephaly, tall forehead with bitemporal narrowing, coarse facial features, hypertelorism, ptosis, downslanting palpebral fissures, short nose with broad base and bulbous tip 1
Dermatologic (cardinal features): Sparse, curly, friable hair; sparse/absent eyebrows with ulerythema ophryogenes (brow erythema with follicle loss); keratosis pilaris; progressive multiple melanocytic nevi (often >100 nevi) 1
Prenatal clues: Increased nuchal lucency, polyhydramnios (77%), premature birth 1
Cardiovascular Management (Critical for Mortality)
At diagnosis, obtain echocardiogram, electrocardiogram, and cardiology consultation immediately - nearly 75% have cardiovascular involvement 1. This is non-negotiable given the mortality risk.
Cardiac Surveillance Protocol
Infancy (up to 1 year):
- If arrhythmias present: 24-hour Holter monitoring 1
- Monitor for pulmonary valvular stenosis (45% prevalence) and hypertrophic cardiomyopathy (40% prevalence) 1
Childhood/adolescence (up to 20 years):
- If no cardiac disease initially: Repeat echocardiogram every 2-3 years 1
- Blood pressure measurement at each visit 1
Adulthood (>20 years):
Critical caveat: Hypertrophic cardiomyopathy in CFC can be rapidly progressive and fatal, sometimes requiring cardiac transplantation 1. Unlike Costello syndrome, arrhythmias are less common but include supraventricular tachycardia, atrioventricular block, and Wolff-Parkinson-White 1. One documented case showed pulmonary hypertension with Grade 3 Heath/Edwards pulmonary vascular changes at autopsy 1.
Multidisciplinary Subspecialty Care
Dermatology
- At diagnosis: Dermatology consultation (virtually all develop cutaneous involvement) 1
- Monitor for progressive melanocytic nevi development
- Manage keratosis pilaris, eczema, hyperkeratosis
- Address heat intolerance and excessive sweating 1
Gastroenterology and Nutrition (Critical for Morbidity)
Feeding difficulties and failure to thrive are prominent, with severe cases requiring aggressive intervention 3:
- Early intervention: Consider nasogastric tube for feeding difficulties 3
- If persistent: Laparoscopic Nissen fundoplication and gastrostomy may be necessary 3
- Growth monitoring: Height and weight Z-scores consistently remain -2 to -3 SD below reference population from infancy through adulthood 4
Important finding: Growth restriction appears independent of feeding modality, growth hormone deficiency status, or specific gene mutation, suggesting other factors like malabsorption, constitutional delay, or cardiac abnormalities 4.
Neurology and Development
- Seizure management: Required in many patients 1
- Developmental support: Intellectual disability is common; early intervention services essential 1
- Behavioral management: Challenging behaviors (self-injury, aggression) are highly prevalent (77%), peaking in adolescence 2
Ongoing Genetics Follow-up
- Annual follow-up with geneticist or specialty Ras pathway clinic 1
- Coordinate multidisciplinary care
- Update family on recurrence risks (autosomal dominant, but most cases are de novo mutations)
Differential Diagnosis Considerations
Distinguish CFC from overlapping RASopathies, as management differs:
- Noonan syndrome: Less severe cognitive delay, fewer cutaneous features, less severe feeding problems 1
- Costello syndrome: Papillomata, multifocal atrial tachycardia more common, ulnar deviation 1
- Noonan with multiple lentigines: Multiple lentigines, sensorineural deafness, cardiac conduction abnormalities 1
The presence of severe ulerythema ophryogenes, extensive nevi, and more severe cognitive/feeding difficulties favor CFC over other RASopathies 1.
Quality of Life Priorities
Focus interventions on:
- Preventing cardiac mortality through vigilant surveillance
- Optimizing nutrition and growth with aggressive feeding support when needed
- Managing challenging behaviors that emerge in adolescence, using function-based approaches
- Coordinating subspecialty care to avoid fragmented management
The comprehensive approach outlined in the 2014 Pediatrics consensus guidelines 1 remains the standard, emphasizing that accurate diagnosis through genetic testing is essential for appropriate medical management and family counseling.